New Win - Sale of IP Portfolio of First-in-Class Non-Opioid Analgesic in clinical stage

Published : 23 Dec 2024

Aagami has been appointed as Advisory, Marketing and Sales Consultant to Trustee of IP Portfolio of First-in-Class Non-Opioid Analgesic in clinical stage. Aagami will support the Sale of this valuable package. 

We bring a unique opportunity to acquire a first-in-class non-opioid analgesic asset CMX-020, now available at a highly attractive price due to unavoidable circumstances. CMX-020 is a groundbreaking small molecule NCE designed for acute and chronic pain management, offering blockbuster potential in a $170+ billion market of Pain Therapy.

Key Highlights of CMX-020:

  1. Disruptive Technology: Eliminates opioid side effects (e.g., addiction, respiratory depression, fatigue) with opioid-equivalent pain relief.
  2. Innovative Multi-Modal Mechanism: CMX-020 mimics natural lipids, activating receptor pathways to release endogenous opioids for pain suppression.
  3. Strong Clinical Profile: Tested in IV and oral formulations with long shelf life (up to 8 years for oral).
  4. High Market Readiness: Projected rapid adoption with clear FDA pathways, strong reimbursement, and high-margin opportunities.
  5. Robust IP Estate: 
    1. US Patents expiring between 2030(5)-2042

i.     US Patents #8,658,632 and #9,096,494

a.     Composition of Matter

b.     Earliest patent filing date: 2010

c.      International expirations 2030

d.     US expiration 2030 (with 5-year FDA extension 2035)

 ii.     US Patent #10,966,937

a.     Composition and oral delivery method including increased bioavailability, stability, tamper-proof,

b.     and drug combination-enabling

c.      Earliest patent filing date: 2016

d.     No international patents

e.     US expiration 2036

iii.     US Patent #11,951,083

a.     New method of manufacturing arachidonic analogs

b.     Earliest patent filing date 2022

c.      No international patents

d.     US expiration 2042

    1. Strong barriers-to-entry with international protections (annuity payments required by May 2025).

Clinical Hold Status & Resolution Path:

  • A metabolic byproduct (DB-130) caused seizureogenic activity in rats/dogs but not in primates or humans.
  • Pathway differences (via FAAH enzyme) have been identified and resolved, and high CMX-020 concentrations in monkeys showed zero seizure activity.
  • FDA requires additional preclinical studies, which the company couldn’t complete due to funding constraints (leading to bankruptcy).


Now, through Aagami, this high-value IP portfolio is available for immediate acquisition at an unmatched price, offering reduced risks, clear regulatory pathways, and substantial market potential. We are pleased to end the year with this news and enter into 2025.

We invite you to evaluate this opportunity and explore its transformative impact on your pain therapy portfolio. Please contact us for more details.

×
Twitter